CCP
ABBV icon

Cassia Capital Partners’s AbbVie ABBV Stock Holding History

Cassia Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Buy
6,954
+318
+5% +$70.5K 0.78% 30
2025
Q4 		$1.52M Sell
6,636
-242
-4% -$55.1K 0.82% 24
2025
Q3 		$1.59M Buy
6,878
+693
+11% +$141K 0.87% 22
2025
Q2 		$1.15M Sell
6,185
-145
-2% -$26.9K 0.69% 31
2025
Q1 		$1.33M Buy
6,330
+272
+4% +$52.9K 0.83% 19
2024
Q4 		$1.08M Buy
6,058
+1,671
+38% +$307K 0.69% 24
2024
Q3 		$866K Sell
4,387
-248
-5% -$46.3K 0.57% 23
2024
Q2 		$795K Buy
4,635
+89
+2% +$14.7K 0.52% 30
2024
Q1 		$828K Buy
4,546
+875
+24% +$151K 0.55% 27
2023
Q4 		$569K Buy
3,671
+125
+4% +$18.2K 0.47% 30
2023
Q3 		$529K Buy
3,546
+74
+2% +$10.9K 0.43% 25
2023
Q2 		$468K Buy
3,472
+1,362
+65% +$200K 0.37% 33
2023
Q1 		$336K Sell
2,110
-47
-2% -$7.19K 0.27% 39
2022
Q4 		$349K Buy
+2,157
New +$331K 0.29% 37

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cassia Capital Partners's ABBV Position: Q1 2026 in Review

Cassia Capital Partners increased its AbbVie (ABBV) stake by 4.8% in Q1 2026, buying an estimated $70.5K and bringing the position to 6,954 shares worth $1.51M. The position accounts for 0.78% of the portfolio, ranked #30.

Cassia Capital Partners first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.59M in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cassia Capital Partners held 6,954 shares of AbbVie worth $1.51M as of Q1 2026.
  • Cassia Capital Partners bought 318 AbbVie shares in Q1 2026, an estimated $70.5K.
  • AbbVie made up 0.78% of Cassia Capital Partners's portfolio in Q1 2026, its #30 holding.
  • Cassia Capital Partners first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Cassia Capital Partners's AbbVie position peaked at $1.59M in Q3 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cassia Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.